title: Visual results following intravitreal Bevacizumab in neovascular age-related macular degeneration.
abstract: OBJECTIVE
  To determine the visual and anatomic outcome of intravitreal Bevacizumab injection in the treatment of neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  Quasi-experimental study.
  
  
  METHODS
  Layton Rahmatulla Benevolent Trust Eye Hospital (LRBT), Lahore, from January to July 2010.
  
  
  METHODS
  Patients who received, one or more intravitreal Bevacizumab injections (1.25 mg per 0.05 ml) for exudative AMD were included in the study. Outcome measures included standardized visual acuity, optical coherence tomography (OCT), macular thickness, intraocular pressure, and blood pressure at 24 or more weeks follow-up. Descriptive statistics were obtained.
  
  
  RESULTS
  Fifty eyes with exudative AMD were observed for six months. The mean VA improved from 0.21 ± 0.11 before injections to 0.43 ± 0.11 after injections at six months. Overall, mean OCT macular thickness decreased by 99 micron at last follow-up. At last follow-up, all eyes received an average of 3.28 ± 0.85 injections. There was no incidence of severe vision loss or adverse effects like endophthalmitis or retinal detachment.
  
  
  CONCLUSIONS
  Intravitreal Bevacizumab has the potential for improvement of vision in exudative AMD for at least 6 months.
authors.affiliation: Department of Ophthalmology, Layton Rahmatulla Benevolent Trust Eye Hospital, Lahore. kashifmd@hotmail.com
authors.forename: Kashif
authors.initials: K
authors.lastname: Iqbal
authors.forename: Jamil
authors.initials: J
authors.lastname: Baig
authors.forename: Ahmad Zeeshan
authors.initials: AZ
authors.lastname: Jamil
authors.forename: Hannan
authors.initials: H
authors.lastname: Jamil
authors.forename: Khurram
authors.initials: K
authors.lastname: Mirza
authors.forename: Tariq
authors.initials: T
authors.lastname: Khan
mesh_terms: D000328:Adult; D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D001794:Blood Pressure; D020256:Choroidal Neovascularization; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence / Q000295:instrumentation / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab